Trientine
Copper Chelator — ALIMENTARY TRACT AND METABOLISM
Also known as: 1,8-Diamino-3,6-diazaoctane, trien, trientine dihydrochloride, trientine HCl, trientine hydrochloride, trientine tetrahydrochloride, triethylene tetramine, triethylene tetramine dihydrochloride, triethylenetetramine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Trientine is an ofp drug in the Copper Chelator class catalogued in DrugCentral. It was first approved by the FDA in 1985. Its mechanism of action is classified as Copper Chelating Activity and Metal Chelating Activity. DrugCentral lists 13 molecular targets, including CA14, CA4 and CA5A. Recorded indications include Plaque psoriasis, Renal cell carcinoma, Scalp psoriasis and Wilson's disease.
- Approval status: ofp (first approved 1985 by the FDA).
- Drug class: Copper Chelator.
- Mechanism of action: Copper Chelating Activity; Metal Chelating Activity.
- Molecular targets: CA14, CA4, CA5A and CA9 (13 listed in DrugCentral).
- Indications: Plaque psoriasis, Renal cell carcinoma, Scalp psoriasis and Wilson's disease.
- ATC code: A16AX12 (Various alimentary tract and metabolism products).
- Molecular formula: C6H18N4; molecular weight 146.24 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (4)
- Plaque psoriasis
- Renal cell carcinoma
- Scalp psoriasis
- Wilson's disease
Off-label uses (1)
- Psoriasis
Contraindications (41)
- Acute hemorrhage
- Acute Thromboembolic Stroke
- Adrenal cortical hypofunction
- Angina pectoris
- Atrophoderma
- Cardiovascular event risk
- Cerebral hemorrhage
- Congenital ichthyosis of skin
- Congenital long QT syndrome
- Diarrhea
- Disorder of calcium metabolism
- Drug-induced hepatitis
- Gastrointestinal fistula
- Gastrointestinal hemorrhage
- Gastrointestinal perforation
- Guttate psoriasis
- Hepatic failure
- Hyperbilirubinemia
- Hypercalcemia
- Hypercalciuria
- Hypertensive disorder
- Hypertensive urgency
- Hypervitaminosis D
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Hypothyroidism
- Iron deficiency anemia
- Liver function tests abnormal
- Myocardial infarction
- + 11 more
Mechanism & targets
| Mechanism of action (MoA) | Copper Chelating Activity; Metal Chelating Activity |
|---|---|
| Established pharmacologic class | Copper Chelator |
Molecular targets (13)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Carbonic anhydrase 14 | CA14 | unknown | Ki 4.92 |
| Carbonic anhydrase 4 | CA4 | unknown | Ki 4.46 |
| Carbonic anhydrase 5A, mitochondrial | CA5A | unknown | Ki 4.42 |
| Carbonic anhydrase 9 | CA9 | unknown | Ki 4.41 |
| Carbonic anhydrase 6 | CA6 | unknown | Ki 4.37 |
| Carbonic anhydrase 7 | CA7 | unknown | Ki 4.35 |
| Carbonic anhydrase 3 | CA3 | unknown | Ki 4.32 |
| Carbonic anhydrase 5B, mitochondrial | CA5B | unknown | Ki 4.31 |
| Carbonic anhydrase 13 | Ca13 | unknown | Ki 4.28 |
| Carbonic anhydrase 12 | CA12 | unknown | Ki 4.24 |
| Carbonic anhydrase 15 | Ca15 | unknown | Ki 4.23 |
| Carbonic anhydrase 2 | CA2 | unknown | Ki 4.19 |
| Carbonic anhydrase 1 | CA1 | unknown | Ki 4.00 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-07-25 | EMA | — | Univar BV | Yes |
| 1985-11-08 | FDA | — | ATON | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A16AX12 | ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Various alimentary tract and metabolism products |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Corneal abrasion | 54.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Trientine is on its molecule page.
| Molecular formula | C6H18N4 |
|---|---|
| Molecular weight | 146.24 g/mol |
| CAS number | — |
| InChIKey | VILCJCGEZXAXTO-UHFFFAOYSA-N |
| PubChem CID | 5565 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Trientine used for?
DrugCentral lists the following indications for Trientine: Plaque psoriasis, Renal cell carcinoma, Scalp psoriasis and Wilson's disease.
How does Trientine work?
Trientine is classified as Copper Chelating Activity and Metal Chelating Activity; its molecular targets in DrugCentral include CA14, CA4, CA5A and CA9.
When was Trientine first approved?
Trientine was first approved by the FDA in 1985.
What drug class does Trientine belong to?
Trientine is in the Copper Chelator class.
What is the chemical formula of Trientine?
Trientine has the molecular formula C6H18N4 and a molecular weight of 146.24 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2738 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3989777 — compound record and bioactivity
- PubChem CID 5565 — chemical identifiers
- DrugBank DB06824 — drug record
- FDA UNII SJ76Y07H5F — substance identity
- DailyMed: FDA labels for Trientine — current prescribing information (label search)
- UniProt Q9ULX7 (CA14) — target protein
- UniProt P22748 (CA4) — target protein
- UniProt P35218 (CA5A) — target protein
- UniProt Q16790 (CA9) — target protein
- UniProt P23280 (CA6) — target protein
- UniProt P43166 (CA7) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.